China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia admin Wed, 01/20/2021 - 16:05
source https://www.pharmatutor.org/pharma-news/2021/china-nmpa-approves-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-for-thalassemia
Subscribe to:
Post Comments (Atom)
-
The National Institutes of Health announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19...
-
Results from a clinical trial published in 2011 confirmed the benefit of using Avastin over laser therapy for treating the most severe c...
-
National Institute for Research in Reproductive Health (NIRRH), formerly known as Institute for Research in Reproduction is a premier res...
No comments:
Post a Comment